Table 3.
Comparison of baseline characteristics of cases with and without amyloid positron emission tomography (PET).
| PET | Total | P | ||
|---|---|---|---|---|
| No | Yes | |||
| N = 298 | N = 64 | N = 362 | ||
| Age at evaluation | 74.2 ± 4.1 | 74.1 ± 4.0 | 74.2 ± 4.1 | 0.833 |
| Gender | 0.625 | |||
| F | 179 (60.1%) | 39 (60.9%) | 218 (60.2%) | |
| M | 119 (39.9%) | 25 (39.1%) | 144 (39.8%) | |
| NSC | 0.557 | |||
| <9 | 50 (16.8%) | 11 (17.2%) | 61 (16.9%) | |
| 9–12 | 136 (45.6%) | 28 (43.8%) | 164 (45.3%) | |
| >12 | 112 (37.6%) | 25 (39.1%) | 137 (37.8%) | |
| Génotype APOE | 0.402 | |||
| 3/2 | 36 (12.1%) | 5 (7.8%) | 41 (11.3%) | |
| 3/3 | 212 (71.1%) | 47 (73.4%) | 259 (71.5%) | |
| 4/3 | 50 (16.8%) | 12 (18.8%) | 62 (17.1%) | |
| MMSE | 28.5 ± 1.3 | 28.5 ± 1.2 | 28.5 ± 1.3 | 0.600 |
| Continuous cognitive | −0.0 ± 3.9 | 0.2 ± 3.5 | 0.0 ± 3.8 | 0.701 |
| score | ||||